Product image of Linagliptina Bluepharma (Linagliptin) supplied by GNH India

Linagliptina Bluepharma

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptina Bluepharma (Linagliptin)

Linagliptin, the active ingredient in Linagliptina Bluepharma, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of blood glucose in adults with type 2 diabetes mellitus, helping to improve glycaemic control when combined with diet and exercise.

GNH India supplies Linagliptina Bluepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bluepharma Genéricos - Comércio De Medicamentos, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptina Bluepharma belongs to the DPP‑4 inhibitor class used to treat type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves blood‑glucose control and reduces HbA1c when added to diet, exercise and other antidiabetic agents.
  • Adjunct to lifestyle therapy: supports achievement of individualized glycaemic targets.
  • Combination therapy: can be co‑administered with metformin, sulfonylureas or insulin to enhance overall glucose‑lowering effect.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the degradation of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced hepatic glucose production and improved post‑prandial glucose control.

Side Effects

Linagliptina Bluepharma may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
  • Headache: transient, mild to moderate intensity.
  • Gastrointestinal discomfort: includes nausea or abdominal pain.
  • Dizziness: occasional light‑headed sensation.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention.
  • Severe hypersensitivity reactions: including rash, angioedema or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Acute kidney injury: sudden decline in renal function, especially in patients with pre‑existing renal disease.
  • Cardiovascular events: rare reports of myocardial infarction or stroke.

Precautions & Warnings

When prescribing Linagliptina Bluepharma, clinicians should consider several safety aspects.

  • Renal impairment: monitor renal function; dose adjustment is not required but caution is advised.
  • Hepatic disease: assess liver enzymes before initiation and periodically thereafter.
  • Pancreatitis history: avoid use in patients with prior pancreatitis episodes.
  • Hypersensitivity: discontinue if signs of allergic reaction appear.
  • Concomitant insulin or sulfonylureas: monitor for hypoglycaemia.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptina Bluepharma can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase linagliptin plasma concentrations.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin exposure.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: heightened risk of hypoglycaemia; adjust dose as needed.
  • Diuretics: may affect renal clearance; monitor renal function.
  • Antihypertensives: observe for additive blood‑pressure effects.
  • Anticoagulants: watch for altered bleeding risk, though data are limited.

Frequently Asked Questions

Linagliptina Bluepharma contains linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels when used together with diet, exercise and other antidiabetic medications.

Linagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally degrades incretin hormones. By preserving incretins such as GLP‑1 and GIP, the drug enhances glucose‑dependent insulin release and suppresses glucagon, leading to reduced hepatic glucose output and better post‑prandial glucose control.

The appropriate dose of Linagliptina Bluepharma is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for linagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin is distinguished by its primarily non‑renal elimination, allowing use without dose adjustment in patients with renal impairment. Its efficacy and safety profile are comparable to other agents in the DPP‑4 class, but the lack of renal dose modification can simplify treatment in certain populations.

Store Linagliptina Bluepharma tablets at ambient temperature, below 25 °C, in the original container. Protect the product from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

Linagliptina Bluepharma is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and significant hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Linagliptina Bluepharma should be avoided in individuals with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for patients with a history of pancreatitis or severe hepatic disease, and it is not recommended for use in children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT